Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AMG562 |
Synonyms | |
Therapy Description |
AMG562 is a bi-specific T-cell engager (BiTE) antibody that binds to CD19 and CD3, potentially resulting in increased T-cell response to CD19-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMG562 | AMG 562|AMG-562 | CD19 Antibody 21 CD3 Antibody 99 | AMG562 is a bi-specific T-cell engager (BiTE) antibody that binds to CD19 and CD3, potentially resulting in increased T-cell response to CD19-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03571828 | Phase I | AMG562 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma | Terminated | USA | DEU | CAN | BEL | 0 |